Bristol-Myers Squibb (NYSE:BMY) saw high single-digit top line growth in 2018, as strong growth in Eliquis and Opdivo sales more than offset the declines in its mature drugs portfolio. The bottom line grew in the low thirties percent, led by higher revenues, lower share count, and lower taxes....
Bristol-Myers Squibb (NYSE:BMY) saw high single-digit top line growth in 2018, as strong growth in Eliquis and Opdivo sales more than offset the declines in its mature drugs portfolio. The bottom line grew in the low thirties percent, led by higher revenues, lower share count, and lower taxes....
Share this Article
Recommended